First, asleif_dufansdottir, note that the article does not go into the medications that the couple took and the known side effects of those medications and how those known side effects relate to the symptoms they experienced.
Secondly, I disagree that people should be tested for HIV before embarking on a sexual relationship. Testing for everything else is very sensible, but HIV???
I suggest that anyone considering an HIV test consider all of the evidence for both sides of the debate before putting themselves at risk of shunning, and pressure from friends, family, GPs etc. to submit to treatment protocols that use some very nasty chemicals.
The Borg, of course, loves this stuff, which should, in itself, create an element of suspicion in their Apostates.
Be suspicious.
This is from http://www.viramune.com/ who are currently updating their website (I wonder why???)
Boehringer Ingelheim Pharmaceuticals, Inc. 2001,
Viramune (nevirapine)
WARNING
"Severe, life-threatening, and in some cases fatal hepatotoxicity, including fulminant and cholestatic hepatitis, hepatic necrosis and hepatic failure, has been reported in patients treated with VIRAMUNE ????. In some cases, patients presented with non- specific prodromal signs or symptoms of hepatitis and progressed to hepatic failure. Some events occurred after short-term exposure to VIRAMUNE. Patients with signs or symptoms of hepatitis must seek medical evaluation immediately and should be advised to discontinue VIRAMUNE. (See WARNINGS)
"Severe, life-threatening skin reactions, including fatal cases, have occurred in patients treated with VIRAMUNE. These have included cases of Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions characterized by rash, constitutional findings, and organ dysfunction. Patients developing signs or symptoms of severe skin reactions or hypersensitivity reactions must discontinue VIRAMUNE as soon as possible. (See WARNINGS)
"The first 12 weeks of therapy with VIRAMUNE are a critical period during which it is essential that patients be monitored intensively to detect potentially life-threatening hepatotoxicity or skin reactions. VIRAMUNE should not be restarted following severe hepatic, skin or hypersensitivity reactions. In addition, the 14-day lead-in period with VIRAMUNE 200 mg daily dosing must be strictly followed. (See WARNINGS)"